Infinity Pharmaceuticals | INFI - Gross Profit On Sales


Infinity Pharmaceuticals reported $231K in Gross Profit on Sales for its fiscal quarter ending in June of 2023.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Cipla INR 39.1B 2.54B Mar/2026
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 63.8M 63.56M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Eisai JPY 153.41B 15.44B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Grifols EUR 766.49M 39.74M Dec/2024
Incyte USD 1.17B 217.51M Mar/2026
Infinity Pharmaceuticals USD 231K 59K Jun/2023
Ionis Pharmaceuticals USD 243M 48M Mar/2026
J&J USD 17.24B 642M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Plus Therapeutics 1.37M 30K Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
TG Therapeutics USD 171.41M 16.98M Mar/2026